Compare CAPR & STRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | STRA |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | 6134 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2011 | 1996 |
| Metric | CAPR | STRA |
|---|---|---|
| Price | $26.10 | $77.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $44.63 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 937.2K | 226.4K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.04% |
| EPS Growth | N/A | ★ 15.85 |
| EPS | N/A | ★ 1.48 |
| Revenue | N/A | ★ $997,137,000.00 |
| Revenue This Year | N/A | $4.71 |
| Revenue Next Year | $3.31 | $4.67 |
| P/E Ratio | ★ N/A | $51.76 |
| Revenue Growth | N/A | ★ 57.23 |
| 52 Week Low | $4.30 | $69.70 |
| 52 Week High | $40.37 | $87.38 |
| Indicator | CAPR | STRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 49.56 |
| Support Level | $25.48 | $76.22 |
| Resistance Level | $30.21 | $83.67 |
| Average True Range (ATR) | 1.40 | 2.12 |
| MACD | 0.33 | -0.03 |
| Stochastic Oscillator | 22.85 | 48.10 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.